Centre Hospitalier Universitaire De Lille
- Address
- lock Available on a paid plan
Cardiovascular and Vascular Research
At Centre Hospitalier Universitaire De Lille, clinical trials in cardiovascular diseases focus on major conditions such as acute coronary syndrome, acute myocardial infarction, heart failure, and transcatheter aortic valve implantation-related care. These studies are designed to test new treatment strategies and improve patient outcomes after serious heart and vessel events.
- Reducing recurrent cardiovascular events after heart attack
- Improving recovery after ST-segment elevation myocardial infarction
- Evaluating safer approaches for aortic stenosis procedures
- Tracking treatment effects in heart failure due to left ventricular systolic dysfunction
Overall, this area combines prevention, recovery, and treatment optimization for people with high-risk cardiac disease.
Pulmonary and Thoracic Oncology
The site has a strong focus on respiratory tract diseases and neoplasms, especially non-small cell lung cancer, small cell lung cancer, pulmonary hypertension, and pulmonary arterial hypertension. Research here is aimed at testing new cancer therapies, improving survival, and finding better ways to control chronic lung conditions.
- Testing new treatments for metastatic non-small cell lung cancer
- Evaluating options for small cell lung cancer and pleural mesothelioma
- Studying therapies for pulmonary arterial hypertension
- Assessing care for chronic obstructive pulmonary disease
These trials reflect a broad effort to advance both thoracic oncology and lung disease management through more effective and targeted approaches.
Hematology and Bleeding Disorders
Clinical research in hemic and lymphatic diseases includes studies in hemophilia A and B and lymphatic malformations. The main goal is to improve disease control, monitor joint health, and evaluate new options for people living with inherited bleeding or lymphatic conditions.
- Assessing joint outcomes in hemophilia patients on preventive treatment
- Exploring therapy for PIK3CA mutation-associated lymphatic malformations
- Supporting better long-term management of bleeding disorders
This research area is centered on practical improvements in symptom control, complication prevention, and quality of life.
Cell Signaling and Rare Disease Research
Work in cell physiological phenomena at the site includes studies of disease mechanisms linked to PIK3CA and c-Met or EGFR alterations. These trials aim to better understand how abnormal cell signaling drives disease and to evaluate more precise treatment options.
- Testing targeted therapy for PIK3CA mutation-related disease
- Evaluating treatment approaches for EGFR exon 20 insertion lung cancer
- Studying c-Met overexpressing non-small cell lung cancer
By focusing on molecular features of disease, this research supports more personalized care for selected cancer and rare disease populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 37 therapeutic areas and 15 of 956 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 897 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 195 by active trials.
lock +194 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Assistance Publique Hopitaux De Paris100trials
lock +128 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Lille
lock Showing 1 of 1 015 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 956 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 54 | Unknown | 2015-07-16 | 2026-02-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.